FDA Has Accepted For Filing The First Potential Once-a-Day Nasal Antihistamine (Medical News Today)
The New Drug Application (NDA) for a newly formulated higher strength azelastine nasal spray has now been accepted by the Food and Drug Administration (FDA) as complete for substantive review after initial evaluation. "This product has the potential to become the first once-a-day nasal antihistamine in the U.S.